Will This News Stop Ocugen Shares in Their Tracks? [The Motley Fool]
Ocugen, Inc. (OCGN)
Company Research
Source: The Motley Fool
Adria Cimino(TMFAdriaCimino)Author BioAdria Cimino grew up with her nose in a book and a love of storytelling. By a twist of fate, she started her career writing about biotech in Boston and discovered that each company is the source of many fascinating stories. Prior to joining The Fool as a contract writer focused on healthcare and consumer goods, Adria covered the stock market for Bloomberg in Paris. When she’s not analyzing companies, she can be found writing fiction or trying to speak French as well as her 9-year-old daughter.Follow @adria_in_parisOcugenNASDAQ:OCGNFrom the start of the year to a peak in February, Ocugen shares rose more than 760%. But in recent weeks, they lost their luster -- at least for some investors. The stock is down about 0% from that peak. And just last week, Ocugen announced news that could remove even more of the luster. Let's take a look what the company said and whether it will put a halt on this once unstoppable stock.Image source: Getty Images.Follo
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy [Yahoo! Finance]Yahoo! Finance
- Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene TherapyGlobeNewswire
- DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmAccesswire
- ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – OCGNGlobeNewswire
- OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors Can Join the Class Action Lawsuit!Accesswire
OCGN
Earnings
- 11/9/23 - Beat
OCGN
Sec Filings
- 4/18/24 - Form S-3
- 4/18/24 - Form S-8
- 4/17/24 - Form 4
- OCGN's page on the SEC website